Outrun Therapeutics unveils lead programme targeting HPV positive head and neck cancer and appoints renowned E3 ligase experts to Scientific Advisory Board (SAB)
- Lead programme based on a first‑in‑class small‑molecule E6AP ubiquitin ligase inhibition strategy for the treatment of HPV‑positive head and neck cancer
- Programme has demonstrated strong in vitro and in vivo proof of mechanism, and is expected to enter the clinic in 2027
- Progress is complemented with formation of world-class SAB, including leading experts in E3 ligase biology and head and neck cancer
Dundee, Scotland – March 17, 2026 – Outrun Therapeutics (“Outrun” or “the Company”), a biotech developing protein stabilising therapeutics identified by its proprietary XL discovery platform, today announces the selection of its lead programme for the treatment of HPV positive head and neck cancer. It also announced the formation of its Scientific Advisory Board comprising world-class experts in E3 ligase biology and head and neck cancer.
